

News Release

Suven Income at INR 4819 Mn; PAT at INR 1294 Mn for the half year ended September 2019

HYDERABAD, INDIA (November 14, 2019)—Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders and Contract Research and Manufacturing Services (CRAMS), today announced its Un-audited Financial Results for the quarter ended 30th September 2019. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th November, 2019 at Hyderabad.

Financial Highlights for the Half year ended September' 2019:

Growth in revenue	INR 4819 Mn vs INR 2949 Mn - up by 62.86%
Growth in PAT	INR 1294 Mn vs INR 567 Mn - up by 128.21%
Growth in EBIDTA	INR 2092 Mn vs INR 974 Mn - up by 114.83%

Financial Highlights for the 2nd Quarter ended September' 2019 (QoQ):

Growth in revenue	INR 2799 Mn vs INR 2020 Mn – up by 38.57%
Growth in PAT	INR 723 Mn vs INR 571 Mn - up by 26.50%
Growth in EBIDTA	INR 1161 Mn vs INR 930 Mn - up by 24.81%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 278 Mn (5.76% on income) for the half year ended September 2019.

Update on patents during this period can be viewed at:

<http://suven.com/Patentupdates.aspx>

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com